155. Lancet and Statin in the Elderly
Questioning Medicine18 Marras 2020

155. Lancet and Statin in the Elderly


https://www.clinicalkey.com/#!/content/journal/1-s2.0-S0140673620322339?scrollTo=%23hl0000424

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32233-9/fulltext

do statins work in old people?? This study in the lancet says-

“In a contemporary primary prevention cohort, people aged 70–100 years with elevated LDL cholesterol had the highest absolute risk of myocardial infarction and atherosclerotic cardiovascular disease and the lowest estimated NNT in 5 years to prevent one event.’

researchers calculated that 80 adults aged 80–100 years — would need to receive a moderate-intensity statin for 5 years to prevent one MI.
and145 adults aged 70–79 years — would need to receive a moderate-intensity statin for 5 years to prevent one MI.
and to prevent just one ASCVD event, the numbers needed to treat were 42 and 88, respectively.

But anytime you read the results you have to say “how did you come up with that number” what were your methods?

In this study they took a sample of people from a large Danish database and these were low risk individuals not on statin therapy. They calculated the number of reduced events by calculating the event rate they expected and dividing it by the number of events during the follow up.

But remember youi have to ask how did you come up with your calculation???

“For these calculations, we assumed 30% and 22% relative risk reduction of myocardial infarction and atherosclerotic cardiovascular disease, respectively, per 1·0 mmol/L reduction in LDL cholesterol in individuals free of atherosclerotic cardiovascular disease, as observed in the Cholesterol Trialist Collaboration meta-analyses.”

THIS IS FRUSTRATING because if you have read the cholesterol trialist you collaboration you know that the individuals in the studies were HONDA they were not low risk individuals. The higher the risk you are the more likely a drug is to work. Think about it like this a statin is more likely to work on someone who is really high risk because they are way more likely to have a MACE. Just like breast cancer chemo therapy is more likely to work on someone who has breast cancer and is even more likely to work if the person is a women.

So in this study they estimated the event rate based on really sick people and then said based on that we can say the likelihood for benefit in these more healthy patients would have a benefit or NNT of 42 or 80 to prevent just one MACE.

NOOOOO you cant take the odds of sick people or people with breast cancer and then say well look how it worked in them so it must work the same way in this population over here.


Do the trial of statins in the elderly or don’t publish the paper

Jaksot(385)

Episode 342: 341.  Methods Monday! What is the problem with stopping a trial EARLY?

Episode 342: 341. Methods Monday! What is the problem with stopping a trial EARLY?

Stopping Trials Early for Benefit: Insights From Recent Pivotal Trials in Chronic Kidney Disease - ScienceDirect   There are 4 major reasons why trials might be stopped early: 1) unequivocal benefit; ...

4 Marras 20248min

Episode 341: 340. ACOI -- Vitamin D and Calcium Made Easy

Episode 341: 340. ACOI -- Vitamin D and Calcium Made Easy

You get the CME knowledge without the CME payment!

30 Loka 202438min

Episode 340: 339. Reaction Risk to Direct Penicillin Challenges

Episode 340: 339. Reaction Risk to Direct Penicillin Challenges

10% of hospitalized patients have penicillin allergy listed in their records, fewer than 1% of patients have true allergies. Use of more-expensive and broader-spectrum antibiotics is associated with l...

29 Loka 20245min

Episode 339: 338. Hypertension Treatment With New Triple Single Pill Combination

Episode 339: 338. Hypertension Treatment With New Triple Single Pill Combination

Efficacy and Safety of a Novel Low-Dose Triple Single-Pill Combination Compared With Placebo for Initial Treatment of HypertensionJ Am Coll Cardiol 2024 Aug 30;[EPub Ahead of Print], A Rodgers, A Sala...

25 Loka 20249min

Episode 338: 337. What is the ideal Vitamin D Level to target?

Episode 338: 337. What is the ideal Vitamin D Level to target?

In 2011, the Endocrine Society published a guideline on “Evaluation, Treatment, and Prevention of Vitamin D Deficiency”   Now, the Society has issued an updated guideline, Demay MB et al. Vitamin D fo...

22 Loka 20245min

Episode 337: 336. 24 Hours After a Stroke for EVT- 2 yr Follow-Up

Episode 337: 336. 24 Hours After a Stroke for EVT- 2 yr Follow-Up

Huijberts I et al. Collateral-based selection for endovascular treatment of acute ischaemic stroke in the late window (MR CLEAN-LATE): 2-year follow-up of a phase 3, multicentre, open-label, randomise...

18 Loka 20246min

Episode 336: 335. Do GLP-1 Cause Residual Gastric Contents

Episode 336: 335. Do GLP-1 Cause Residual Gastric Contents

Because glucagon-like peptide-1 (GLP-1) receptor agonists can slow gastric emptying, they might confer risk for residual gastric contents — and possibly aspiration!!!! Should we stop the glp-1 Should ...

10 Loka 20245min

Episode 335: 334. Do Thicken Liquids Prevent Dysphagia?

Episode 335: 334. Do Thicken Liquids Prevent Dysphagia?

Oropharyngeal dysphagia is highly prevalent in hospitalized patients with Alzheimer disease or other dementias. These patients often are prescribed thick liquid diets Makhnevich A et al. Thick liquids...

8 Loka 20245min

Suosittua kategoriassa Terveys ja hyvinvointi

unicast
psykopodiaa-podcast
tiedenaiset-podcast
voi-hyvin-meditaatiot-2
vakeva-elama-viisaampi-mieli-vahvempi-keho
rss-pitaisko-erota
rss-narsisti
puhu-muru
rss-kuumilla-aalloilla
rss-pt-paahtio
meditaatiot-suomeksi
selviytyjat-tarinoita-elamasta
terapiassa
rss-nautinto
audio-sport-juoksu
rss-rentoudu-podcast-rentoutumiseen-hanna-viljanmaa
fitnesskulmapodcast
fitnessvastaanotto
rss-addiktit
rss-kyykkya-ja-kuoharia